Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report : By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Component, By Method, By Application, By End Use, By Region – Market Forecast, 2026–2034

The non-invasive prenatal testing market size is expected to reach USD 12.47 billion by 2034, according to a new study by Polaris Market Research. The report “Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Component, By Method, By Application, By End Use, By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-invasive prenatal testing (NIPT) is used to screen for certain genetic conditions in a fetus, such as Down syndrome. The method uses a blood sample from the pregnant individual. This test analyzes small fragments of fetal DNA circulating in the maternal blood. NIPT is preferred for its accuracy and safety compared to invasive methods.

The growing importance of early detection of genetic disorders fuels the NIPT market growth. Significant advancements in genomic technology and bioinformatics also propel the growth. Improvements in next-generation sequencing (NGS) technology have enhanced the accuracy and efficiency of fetal DNA analysis. These innovations have led to more affordable and accessible NIPT options. Thus, technological advancements are expanding NIPT adoption among healthcare providers and patients.

The non-invasive prenatal testing market is driven by intense competition with strategies including price competitiveness and technological innovation with strategic partnerships. In October 2024, Yourgene Health set up the first NIPT workflow at Genetix in Colombia. This service will provide quick, accurate NIPT results for expectant parents in Colombia. It will be used to reduce turnaround times and delivery problems.

Non-Invasive Prenatal Testing (NIPT) Market Report Highlights

By method analysis, the cell-free DNA in maternal plasma tests segment dominated the market in 2025 with 45.15%. CfDNA offers minimal risk and superior accuracy than traditional invasive methods. These benefits contributed to the segment growth.

By application, the trisomy segment led with 55.10% revenue share in 2025. This is due to NIPT's rising use for detecting common chromosomal abnormalities.

North America led the market with 44.92% in 2025. The dominance is attributed to advanced healthcare infrastructure and high awareness levels. Robust adoption of advanced technologies also fuel the regional market growth.

Asia Pacific is expected to register the fastest CAGR of 12.6%. The expansion is driven by economic growth, technological innovation, geographic expansion, and strategic partnerships.

The key market players include Agilent Technologies, Inc.; Centogene N.V.; Eurofins LifeCodexx GmbH; F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics); Illumina, Inc.; Laboratory Corp. of America Holdings; MedGenome Labs Ltd.; Myriad Women’s Health, Inc.; Natera, Inc.; Progenity, Inc.; Qiagen; Quest Diagnostics, Inc.; and Thermo Fisher Scientific, Inc.

Where is the NIPT Market Headed?

The market is expected to experience strong growth due to an expanding clinical scope and improvements in technology. Future trends include the shift from aneuploidy screening to genome-wide analysis. This shift allows for the detection of microdeletions, rare chromosomal abnormalities, and single-gene disorders. The integration of AI and bioinformatics will improve result accuracy and lower false positives. Reducing costs through workflow automation and high-throughput platforms will make these technologies more accessible in emerging markets. Furthermore, the growing use in low-risk pregnancies and increasing reimbursement support will widen the target population. Developing non-invasive whole-genome sequencing and point-of-care solutions will create attractive opportunities. Partnerships between diagnostics companies and healthcare providers will also speed up market growth, especially in Asia Pacific and Latin America.

What Non Invasive Prenatal Testing Market Report Reveals?

What is the global market size, growth trend, and CAGR for the market through 2034?

What are the market drivers, opportunities, and restraints of the market growth?

How AI integration impacts the industry?

How does the demand for different methods influence the market landscape?

How does the market differ in gestation period, component, method, application, end use, and geography? What is the leading application?

What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?

Who are the key players, and what is their relative position in terms of competitive positioning?

Polaris Market Research has segmented the non-invasive prenatal testing market report based on gestation period, component, method, application, end use, and region:

By Gestation Period Outlook (Revenue – USD Billion, 2021–2034)
0–12 Weeks
13–24 Weeks

25–36 Weeks

By Component Outlook (Revenue – USD Billion, 2021–2034)

Consumables

Instruments

Software

Services

By Method Outlook (Revenue – USD Billion, 2021–2034)

Cell-Free DNA in Maternal Plasma Tests

Ultrasound Detection

Biochemical Screening Tests

Others

By Application Outlook (Revenue – USD Billion, 2021–2034)

Monosomy

Trisomy

Microdeletion Syndrome

Others

By End Use Outlook (Revenue – USD Billion, 2021–2034)

Diagnostic Centers

Hospitals and Clinics

Others

By Regional Outlook (Revenue – USD Billion, 2021–2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of the Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more